Divi's Laboratories (DIVISLAB) — Financial Results

Divi's Laboratories reported Q1 FY2026 consolidated revenue of ₹2,529 crores, up 15.1% YoY, with net profit reaching ₹545 crores, up 26.7% YoY. The company demonstrated operational strength through its backward-integrated model, Unit 3 facility operational since January 2025, and strategic focus on custom synthesis and GLP-1 platforms. Capacity utilization stands at 80%. Management guided ₹2,000 crores total capex for FY2026 backed by long-term supply commitments, with peptide commercialization expected within 6-8 months and three large custom synthesis projects under development.

📄 View Original Announcement (PDF)

📊 Stock Analysis — DIVISLAB ✨ Ask AI About This

About Divi's Laboratories Limited (DIVISLAB)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,79,470.03 Cr P/E: 72.4 ROE: 16.6% ROCE: 22.1%

View full DIVISLAB stock details →

📡 Get AI alerts when DIVISLAB files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DIVISLAB — Free

💡 Ask AI about this filing

"How does this financial results affect Divi's Laboratories Limited's outlook?" "What did Divi's Laboratories Limited announce on 12 August 2025?" "Is this positive or negative for DIVISLAB?"

Ask AI Free →

📊 More DIVISLAB filings

See all DIVISLAB filings →

🔥 Also filed on 12 August 2025

ZYDUSLIFE Zydus Lifesciences Limited Financial Results TATAPOWER Tata Power Company Limited Announcement ZYDUSLIFE Zydus Lifesciences Limited Financial Results ZYDUSLIFE Zydus Lifesciences Limited Financial Results ZYDUSLIFE Zydus Lifesciences Limited Financial Results APOLLOHOSP Apollo Hospitals Enterprise Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DIVISLAB files new disclosures

Track DIVISLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.